Educational

By Andrew Kantor

The whole issue of compounding GLP-1 agonists like semaglutide is fraught with land mines and misinformation — disinformation, even.

It's good, then, that the Game Changers Pharmacotherapy Podcast had a couple of guests who know what they're talking about to clear some of the air: Tenille Davis, PharmD, RPh (chief advocacy officer for the Alliance for Pharmacy Compounding) and Scott Brunner, CAE (CEO of APC). The host — Geoff Wall, PharmD — has the chops, too; he's a professor of pharmacy practice at Drake University.

It covers everything you need to know about compounding GLP-1s, including access, cost, and how shortages come into play. Even better, you might be able to get a half-hour of CPE credit, too!

Check out "Compounded GLP1s" on the Game Changers podcast — click

BY ANDREW KANTOR

Some important updates regarding quality standards and changes to the United States Pharmacopeia (USP) standards are coming that may impact your practice.

To give some background, pharmacies in the Revelation Pharma Network follow standard operating procedures that are built around processes developed by USP. While USP is not a regulatory agency and does not carry the force of law, many state boards of pharmacy as well as the FDA recognize USP’s compounding standards as the measure of quality assurance that a compounding pharmacy should follow.

On November 1, 2023, new editions of USP chapters pertaining to nonsterile, sterile, and hazardous drug compounding will become compendially applicable, meaning that they are the most current versions and regulatory agencies may choose to adopt them.

It is important to note that these new editions are not simple modifications but are largely complete re-writes of the current